# Brooklyn Investment Group

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/brooklyn-investment-group
Canonical HTML page: https://getbiobrief.com/entity/brooklyn-investment-group

## Recent coverage (1 stories)

### I-Mab Posts $(0.16) EPS; $9 PT Implies 371% Upside
2026-08-22 07:00:16 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

I-Mab, a clinical-stage oncology and immunology biotech, reported a $(0.16) quarterly EPS on Aug 20. With shares at $1.91, H.C. Wainwright's reiterated $9 target implies massive upside, though Weiss remains bearish. Institutional ownership sits at 38.38%.
Full story: https://getbiobrief.com/story/imab-nbp-q3-2026-earnings-biotech-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.